Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ASCO: BioNTech and Merck Present Positive Data on China-Sourced Oncology Drugs

publication date: Jun 5, 2023

Two western biopharmas, Germany’s BioNTech and US-based Merck, reported early results at ASCO for antibody drug conjugate therapeutics they in-licensed from China companies. ADCs are currently biotech’s hottest drug development field, and the two companies each bolstered their pipelines with candidates from China biopharmas. BioNTech said DB-1303, its topoisomerase-1 inhibitor DC acquired from Shanghai DualityBio, showed encouraging improvement in HER2-positive breast cancer patients. Merck’s SKB264, an anti-TROP2 ADC in-licensed from Kelun-Biotech, was effective and safe for NSCLC patients in a Phase II trial. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital